Newswire (Published: Tuesday, July 4, 2017, Received: Friday, June 30, 2017, 1:30:40 AM CDT)

Word Count: 466

Data from Huazhong University of Science and Technology Advance Knowledge in Prostate Cancer (Calpain and AR-V7: Two potential therapeutic targets to overcome acquired docetaxel resistance in castration-resistant prostate cancer cells)

By a News Reporter-Staff News Editor at Cancer Weekly -- Current study results on Oncology - Prostate Cancer have been published. According to news reporting originating from Hubei, People's Republic of China, by NewsRx correspondents, research stated, "Docetaxel-based chemotherapy has been widely used as the first-line treatment for castration-resistant prostate cancer (CRPC) patients. However, the mechanisms of docetaxel-resistance remain unclear."

Our news editors obtained a quote from the research from the Huazhong University of Science and Technology, "In the present study with the establishment of 2 in vitro models of docetaxel-resistant CRPC cell sublines, we firstly reported that activation of calpain may play a promotional role in the resistance of docetaxel in prostate cancer, meanwhile using the calpain inhibitor combined with docetaxel improved the efficiency of docetaxel in docetaxel-resistant cell sublines. Moreover, we also found that the expression of androgen-independent constitutively and transcriptionally active androgen receptor splice variant-7 (AR-V7) remained high in the docetaxel-resistant CRPC cell subline Rvl-DR, and that it may be involved in acquired docetaxel-resistance of CRPC. However, a novel importin-P inhibitor (importazole) was only capable of slightly decreasing the transcriptional activity of the AR signaling pathway via blocking nuclear import of AR-FL and various non-specific AR-Vs, instead of AR-V7."

According to the news editors, the research concluded: "These findings suggest that calpain and AR-V7 may serve as important biomarkers in the treatment of CRPC, and targeting calpain and AR-V7 may provide a new approach in overcoming docetaxel-resistance."

For more information on this research see: Calpain and AR-V7: Two potential therapeutic targets to overcome acquired docetaxel resistance in castration-resistant prostate cancer cells. Oncology Reports, 2017;37(6):3651-3659. Oncology Reports can be contacted at: Spandidos Publ Ltd, Pob 18179, Athens, 116 10, Greece (see also Oncology - Prostate Cancer).

The news editors report that additional information may be obtained by contacting X.P. Zhang, Huazhong University of Science & Technology, Union Hosp, Dept. of Urol, Tongji Med College, Wuhan 430022, Hubei, People's Republic of China. Additional authors for this research include N. Lou, X. Li, G.H. Xu, H.L. Ruan, W. Xia, B. Qiu, L. Bao, C.F. Yuan, X.M. Huang, K.S. Wang, Q. Cao, K. Chen, H.M. Yang and L. Liu.

Keywords for this news article include: Hubei, People's Republic of China, Asia, Cysteine Endopeptidases, Enzymes and Coenzymes, Prostatic Neoplasms, Peptide Hydrolases, Prostate Cancer, Oncology, Calpain, Huazhong University of Science and Technology.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC


Huazhong University of Science & Technology


Eastern Asia
Southern Europe
People's Republic of China


Science and Technology
      Scientific Research
            Pharmaceutical and Drug Development Technology
Health and Wellness
      Medical Conditions and Diseases
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Health Sciences
            Pharmaceutical and Drug Development Technology
      Treatments and Therapies